Latest news for RION (OTC:RIOXF) Stock

RION Co Ltd is engaged in manufacturing and selling of maintenance services of a medical device. The company offers hearing instruments and medical equipment, an environmental device including sound and vibration measuring instruments and particle counters and parts and equipment.

RION Co Ltd

- 71 patients dosed in the potentially pivotal Phase 2 clinical study of firicabtagene autoleucel (firi-cel); Interim analysis results expected to be reported in 1H'25 -
- IND application for CRG-023, CARGO's tri-specific CAR T, cleared by the FDA; Phase 1 study enrollment expected to initiate mid-year 2025 -
- CARGO announces novel allogeneic platform based on a universal allogeneic-enabling vector intended to be paired with any new or existing CAR vector to create an allogeneic CAR T-cell therapy while leveraging existing autologous drug product processes -&nbsp; &nbsp;
 SAN CARLOS, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=ARZMJrK8j2BjKZzS_L10hQx5YAo4VCSXKkxHEiE4gMCdpf6MR9EnLIv9y1XRPZkFK1RH_JTLy8h9_CM7AuErzA3FqHObWkzEp5_hPSseszA=">CARGO Therapeutics, Inc</a>. (NASDAQ:<a href="https://www.benzinga.com/stock/CRGX#NASDAQ">CRGX</a>), a clinical-stage biotechnology company positioned to advance next-generation, potentially curative cell therapies for cancer patients, today provided a corporate update and anticipated milestones for 2025.

Biotech

News

General

CRGX

CARGO Therapeutics Reports 71 Patients Dosed In Phase 2 Firicabtagene Autoleucel Study; Interim Results Expected H1'25; FDA Clears IND For CRG-023, Phase 1 Enrollment Mid-2025; Announces Novel Allogeneic Platform For CAR T-Cell Therapy

CASH

CASK

CORRECTION: Heritage Distilling Ticker Is 'CASK'

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

Heritage Distilling Board Approves Bitcoin Treasury Policy

Guidance

TD SYNNEX Sees Q1 Adj. EPS $2.65 - $3.15 vs $2.95 Est., Revenue $14.4B - $15.2B vs $14.769B Est.

The Company reported the following results on a preliminary and unaudited basis2:
<ul>
<li>Net sales for the fourth quarter increased 5.0% to $402.0 million</li>
<li>Constant currency net sales3 for the fourth quarter increased 6.0% to $405.9 million, with the United States ("U.S.") increasing 10.5% and Canada decreasing 0.2%</li>
<li>Comparable store sales for the fourth quarter increased 1.6%, with the U.S. increasing 4.7% and Canada decreasing 2.5%</li>
<li>Net sales for fiscal 2024 increased 2.5% to $1.54 billion</li>
<li>Constant currency net sales3 for fiscal 2024 increased 3.1% to $1.55 billion, with the U.S. increasing 6.7% and Canada decreasing 1.6%</li>
<li>Comparable store sales for fiscal 2024 decreased 0.1%, with the U.S. increasing 2.7% and Canada decreasing 4.0%</li>
</ul>
Based on the preliminary fourth quarter and fiscal 2024 net sales results outlined above, the Company reaffirms its previously provided fiscal 2024 Adjusted earnings before interest, taxes, depreciation and amortization ("Adjusted EBITDA")1 outlook of approximately $290 million to $300 million.

Company Reports Q4 Net Sales Up 5% To $402M; U.S. Sales Rise 10.5%, Canada Falls 0.2%; Fiscal 2024 Sales Up 2.5% To $1.54B; Reaffirms EBITDA Outlook Of $290M-$300M

HC Wainwright &amp; Co. analyst Andrew Fein maintains Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with a Buy and raises the price target from $30 to $35.

Price Target

Analyst Ratings

CPRX

HC Wainwright & Co. Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $35

-- Additional data from BROADWAY, BROOKLYN, and TANDEM to be presented throughout 2025; expected to support global regulatory filings for obicetrapib, including EMA submission in 2H25 by our partner Menarini –
-- Data from Phase 2 VINCENT trial expected by 2H25, which explores effect of obicetrapib alone and in combination with a PCSK9i on Lp(a) –
-- Focus on commercial readiness with manufacturing capacity establishment and inventory build-out --
-- Year end, unaudited, cash balance of $835 million following oversubscribed public offering in December 2024 --
NAARDEN, The Netherlands and MIAMI, Jan. 10, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMS#NASDAQ">NAMS</a>), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today provided an update on the obicetrapib clinical development program and outlined its strategic priorities for 2025.
NewAmsterdam is developing obicetrapib, an oral, low-dose, once-daily, and highly selective cholesteryl ester transfer protein ("CETP") inhibitor, alone or as a fixed-dose combination with ezetimibe, as preferred LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of cardiovascular disease with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.&nbsp;The Company's global, pivotal Phase 3 clinical development program consists of four trials in over 12,250 patients.

NAMS

NewAmsterdam Pharma Outlines 2025 Strategy With Obicetrapib Focus; Expects EMA Filing In H2 2025, Unveils $835M Year-End Cash. Highlights: BROADWAY 33% LDL-C Reduction, TANDEM 49% Reduction, BROOKLYN 36% Reduction; PREVAIL Trial Ongoing. VINCENT & REMBRANDT Trials To Conclude In 2025, 2027.

INSM

Insmed Provides Outlook Ahead Of J.P. Morgan Healthcare Conference; Sees 2025 Global ARIKAYCE Revenues $405M-$425M

Preliminary unaudited fourth quarter 2024 net revenue expected to be approximately $12 million to $12.3 million, representing 99% growth over Q4 2023 at the mid-point of the range
Fourth quarter 2024 Gross-to-net (GTN) discount expected to be in the range of 18% to 19%
Preliminary unaudited full year 2024 net revenue expected to be approximately $36.2 million to $36.5 million, compared to $13.6 million for full year 2023
BURLINGTON, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCPH#NASDAQ">SCPH</a>) (the "Company"), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced preliminary results for the fourth quarter and full year 2024, including fourth quarter 2024 net FUROSCIX revenue and unaudited cash and cash equivalents.

Earnings

SCPH

scPharmaceuticals Reports Preliminary Q4 Revenue Of $12M-$12.3M; FY24 Revenue Expected To Be $36.2M-$36.5M

HURC

Hurco Cos Q4 EPS $(0.23) Down From $0.36 YoY, Sales And Service Fees $53.7M Down From $66.11M YoY

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">89.2000</td>
<td align="right">1.17</td>
<td align="right">1.32</td>
<td>33.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">76.3900</td>
<td align="right">0.38</td>
<td align="right">0.49</td>
<td>13.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">223.3000</td>
<td align="right">0.29</td>
<td align="right">0.13</td>
<td>603</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">140.5199</td>
<td align="right">0.09</td>
<td align="right">0.06</td>
<td>1.5K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">232.4200</td>
<td align="right">-1.460</td>
<td align="right">-0.63</td>
<td>23.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">48.2736</td>
<td align="right">-0.216</td>
<td align="right">-0.45</td>
<td>91.7K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alert provides traders with a compiled way to read macro-level market trends. Investors garner a particular interest in sector movers to better determine sectors that are over- or under-performing to make better investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
To read more about sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

Movers

ETFs

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For January 10, 2025

Rosenblatt analyst Barton Crockett maintains Liberty Formula One Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWONK#NASDAQ">FWONK</a>) with a Buy and raises the price target from $93 to $102.

FWONK

Rosenblatt Maintains Buy on Liberty Formula One Gr, Raises Price Target to $102

Genius Group Adds $5M To Bitcoin Treasury

ARCT

Arcturus Therapeutics Initiates Phase 1 H5N1 Flu Vaccine Trial

Current Co-Chairman of the Board will now also serve as Chief Executive Officer
Pulse Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation&#x2122; (nano-PFA or nsPFA&#x2122;) technology, today announced the appointment of Paul A. LaViolette, current Co-Chairman of the Board, as Chief Executive Officer.

Management

PLSE

Pulse Biosciences Appoints Paul LaViolette As Chief Executive Officer

TYRA

Tyra Biosciences Receives IND Clearance From The FDA To Proceed With A Phase 2 Study Of TYRA-300 In Non-Muscle Invasive Bladder Cancer

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Kamada (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>) with a Buy and maintains $11 price target.

Reiteration

KMDA

HC Wainwright & Co. Reiterates Buy on Kamada, Maintains $11 Price Target

Contracts

Nano Labs Subsidiary Nano Bit, BitFi Enter Strategic Partnership; Nano Labs Agrees To Adopt Bitcoin As A Long-Term Strategic Reserve Asset, With Nano Bit Responsible For The Management And Operation Of These Assets

RVTY

Revvity Receives FDA Clearance For EUROIMMUN's Free Testosterone Test

TLSA

Tiziana Life Sciences Announced Findings On Benefits Of Its Nasal Anti-CD3 Monoclonal Antibody In Sustaining Tissue Homeostasis And Mitigating The Side Effects Associated With GLP-1 Agonists Discontinuation

RION

Comments

RION

News

Latest news for RION (OTC:RIOXF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga